Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Current Deferred Revenue (2024 - 2025)

Camp4 Therapeutics' Current Deferred Revenue history spans 2 years, with the latest figure at $9.4 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 2338.18% year-over-year to $9.4 million; the TTM value through Dec 2025 reached $9.4 million, up 2338.18%, while the annual FY2025 figure was $9.4 million, 2338.18% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $9.4 million at Camp4 Therapeutics, up from $385000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $9.4 million in Q4 2025 and bottomed at $385000.0 in Q4 2024.